IL-21 and other serum proinflammatory cytokine levels in patients with multiple myeloma at diagnosis

Journal of Postgraduate Medicine

Volumn 60, Issue 2, 2014, Pages 141-144

  Mehtap, O ^a   Atesoglu, E B ^a   Tarkun, P ^a   Hacihanefioglu, A ^a   Dolasik, I ^a   Musul, M M ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

IL 1 ; IL 21; IL 6; Multiple myeloma; TNF

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN DERIVATIVE;

ARTICLE; BONE DISEASE; BONE LESION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRACTURE; HUMAN; MULTIPLE MYELOMA; ANALYSIS OF VARIANCE; BLOOD; CASE REPORT; FEMALE; IMMUNOLOGY; MALE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKINS; MALE; MULTIPLE MYELOMA; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901404450     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.132319     Document Type: Article

References (26)

1. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6: 273-84.
2. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332: 83-5.
3. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73: 517-26.
4. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983;306: 378-80.
5. Bertolini DR, Nedwin GE, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factor. Nature 1986;319: 516-8.
6. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol 1990;74: 424-31.
7. Hata H, Matsuzaki H, Takatsuki K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Haematol 1990;83: 133-6.
8. Sawamura M, Murakami H, Tsuchiya J. Tumor necrosis factor-alpha and interleukin 4 in myeloma cell precursor differentiation. Leuk Lymphoma 1996;21: 31-6.
9. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408: 57-63.
10. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 2000;97: 11439-44.
11. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002;99: 3756-62.
12. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004;173: 5361-71.
13. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265: 621-36.
14. Yokoe T, Iino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: Preliminary report. Breast Cancer 2000;7: 187-90.
15. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, et al. Interleukin-6 blood levels is associated with circulating carcinoembryonic antigen and prognosis in patientS with colorectal cancer. Ann Surg Oncol 2000;7: 133-8.
16. Zhang GJ, Adachi I. Serum interleukin-6 Levels correlate in tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999;19: 1427-32.
17. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters. Ann Hematol 1991;62: 54-8.
18. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84: 2008-11.
19. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin 6 is a prognostic factor in multiple myeloma. Blood 1991;77: 2794-5.
20. Merico F, Bergui L, Gregoretti MG, Ghia P, Aimo G, Lindley IJ, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993;92: 27-31.
21. Kiss TL, Lipton JH, Bergsagel DE, Meharchand JM, Jamal N, Minden MD, et al. Determination of IL6, IL1 and IL4 in the plasma of patients with multiple myeloma. Leuk Lymphoma 1994;14: 335-40.
22. Ballester OF, Moscinski LC, Lyman GH, Chaney JV, Saba HI, Spiers AS, et al. High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma. Blood 1994;83: 1903-8.
23. Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: An overview of clinical and experimental data. Cytokine 2001;16: 79-86.
24. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002;17: 1921-5.
25. Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, et al. Serum Proinflammatory Mediators at Different Periods of Therapy in Patients With Multiple Myeloma. Mediators Inflamm 2005;2005: 171-4.
26. Emile C, Fermand JP, Danon F. Interleukin-6 serum levels in patients with multiple myeloma. Br J Haematol 1994;86: 439-40.